Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Stomach Neoplasms 12Colorectal Neoplasms 12Breast Neoplasms 12Pancreatic Neoplasms 10Leukemia, Myeloid, Acute 10Neoplasm Metastasis 9Lung Neoplasms 9Hematologic Neoplasms 9Head and Neck Neoplasms 9Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Neoplasms 8Endometrial Neoplasms 8Myasthenia Gravis 7Melanoma 7Uterine Cervical Neoplasms 6Recurrence 6Rectal Neoplasms 6Neoplasms by Site 6Neoplasms by Histologic Type 6Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Neoplasms, Plasma Cell 5Infections 5Colonic Neoplasms 5

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Muscle Invasive Bladder Urothelial Carcinoma × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡